ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Midazolam

Also written as “midazolam”, “USL261” and “SHP615”.

Its studies are mostly in Epilepsy · HIV Infections · Diabetes Mellitus, Type 2 · Neoplasms · Nervous System Diseases, led by 10 companies.

Drug pageMidazolam: every studyMany companies study it; this page follows only the 18 they lead. All 426 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 1, 200818 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only30 open or runningphase 1since Jul 1, 2008Jul 1, 2008none ahead
Merckits history only30 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
Takedaits history only30 open or runningphase 3since Nov 6, 2017Nov 6, 2017none ahead
Hamad Medicalits history only20 open or runningphase 4since Sep 4, 2016Sep 4, 2016none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Oct 2, 2015Oct 2, 2015none ahead
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 1since Aug 9, 2018Aug 9, 2018none ahead
Orion Corporation, Orion Pharmaits history only10 open or runningphase 3since May 31, 2007May 31, 2007none ahead
Phathom Pharmaceuticalsits history only10 open or runningphase 1since Sep 4, 2020Sep 4, 2020none ahead
Rafa Laboratoriesits history only10 open or runningphase 1since Dec 15, 2020Dec 15, 2020none ahead
The Emmesits history only10 open or runningphase 3since Apr 27, 2005Apr 27, 2005none ahead

Also a collaborator on its studies: Arvinas Estrogen Receptor, National Resilience, Takeda Development Center Americas, PRA Health Sciences, Medpace, Premier Research Group and Cross Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Apr 27, 2005.

  1. Mar 10, 2009Phase 1 study in Healthy Male VolunteerAstraZeneca · NCT00859352 · 28 enrolled · Sweden
  2. Jun 17, 2015Merck’s first study: phase 1 study in Skin Diseases, BacterialNew to MerckMerck · NCT02477514 · 18 enrolled
  3. Oct 2, 2015Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02568176 · 71 enrolled · Belgium
  4. Jun 2, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02791815 · 20 enrolled · France
  5. Sep 4, 2016Hamad Medical’s first study: phase 4 study in SeizuresNew to Hamad MedicalHamad Medical · NCT02897856 · 150 enrolled · Qatar
  6. Oct 12, 2017Phase 1 study in Renal InsufficiencyMerck · NCT03311841 · 32 enrolled · United States
  7. Nov 6, 2017Takeda’s first studies: 2 phase 3 studies in Nervous System DiseasesNew to TakedaTakeda · NCT03336645, NCT03336450
  8. Jan 29, 2018Phase 1 study in CarcinomaTakeda · NCT03420742 · 24 enrolled · France, Italy, Netherlands and more
  9. Aug 9, 2018Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03628339 · 12 enrolled · Germany
  10. Sep 4, 2020Phathom Pharmaceuticals’ first study: phase 1 study in Healthy VolunteersNew to Phathom PharmaceuticalsPhathom Pharmaceuticals · NCT04545944 · 20 enrolled · United States
  11. Sep 10, 2020Phase 3 study in Pain, ProceduralHamad Medical · NCT04571879 · 48 enrolled · Qatar
  12. Dec 15, 2020Rafa Laboratories’ first study: phase 1 study in Status EpilepticusNew to Rafa LaboratoriesRafa Laboratories · NCT04679623 · 40 enrolled · United States
  13. Jul 1, 2021Phase 1 study in Solid TumourAstraZeneca · NCT04958226 · 21 enrolled · United States
  14. Aug 26, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungMerck · NCT06575933 · 28 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
ciprofolruleHaisco Pharmaceutical Groupphase 436
AlprazolamruleViatrisphase 435
brexanoloneruleSupernus Pharmaceuticalsphase 414
DiazepamruleAcorda Therapeuticsphase 39

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06575933Carcinoma, Non-Small-Cell Lung · United States1CompletedMerckOct 28, 202428
NCT04958226Solid Tumour · United States1CompletedAstraZenecaFeb 6, 202321
NCT04679623Status Epilepticus · United States1CompletedRafa LaboratoriesSep 17, 202140
NCT04571879Pain, Procedural · Qatar3UNKNOWNHamad MedicalDec 30, 202348
NCT04545944Healthy Volunteers · United States1CompletedPhathom PharmaceuticalsNov 13, 202020
NCT03628339Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyOct 25, 201812
NCT03420742Carcinoma · France, Italy, Netherlands and more1CompletedTakedaMar 24, 202024
NCT03336645Nervous System Diseases · Japan3CompletedTakedaAug 19, 201925
NCT03336450Nervous System Diseases · Japan3CompletedTakedaOct 13, 20203
NCT03311841Renal Insufficiency · United States1CompletedMerckAug 2, 201832
NCT02897856Seizures · Qatar4CompletedHamad MedicalNov 2018150
NCT02791815Healthy Subjects · France1CompletedJohnson & JohnsonSep 201620
NCT02568176Healthy · Belgium1CompletedJohnson & JohnsonFeb 201671
NCT02477514Skin Diseases, Bacterial1CompletedMerckAug 201518
NCT00859352Healthy Male Volunteer · Sweden1CompletedAstraZeneca28
NCT00709553Healthy · Germany1CompletedAstraZenecaAug 200812
NCT00481312Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Estonia, Finland and more3CompletedOrion Corporation, Orion PharmaAug 2009501
NCT00109395Critical Illness · United States3CompletedThe EmmesSep 2007179

How it is read

Names in the registry

  • “Midazolam”, 64 entries
  • “midazolam”, 13 entries
  • “USL261”, 4 entries
  • “SHP615”, 2 entries
  • “Midazolam Solution”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.